PT Magna Investama Mandiri Tbk (IDX:MGNA)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	5,620	5,620	-2,021	-3,027	-2,309	53,146
Depreciation & Amortization	3,662	3,662	3,507	3,548	3,651	39.27
Other Operating Activities	-4,506	-752.66	8,341	-239.47	-15,411	-60,273
Operating Cash Flow	4,776	8,530	9,828	281.52	-14,068	-7,088
Operating Cash Flow Growth	-44.53%	-13.21%	3390.94%	-	-	-
Capital Expenditures	-352.75	-667.03	-134.92	-16.81	-3.9	-
Sale of Property, Plant & Equipment	-	-	-	-	-	110,137
Investment in Securities	-	-9,000	-	-108,210	-	-
Other Investing Activities	-1,300	-1,300	-	-	10,427	-
Investing Cash Flow	-1,653	-10,967	-134.92	-108,226	10,423	110,137
Short-Term Debt Issued	-	-	-	-	-	2,800
Long-Term Debt Issued	-	12,299	14,396	-	-	-
Total Debt Issued	5,170	12,299	14,396	-	-	2,800
Long-Term Debt Repaid	-	-12,183	-12,986	-6,140	-8,483	-105,972
Net Debt Issued (Repaid)	-5,318	115.4	1,409	-6,140	-8,483	-103,172
Issuance of Common Stock	0.1	0.09	0	120,370	-	-
Other Financing Activities	-5,080	-17,384	-	1,975	11,775	-
Financing Cash Flow	-10,397	-17,269	1,409	116,205	3,292	-103,172
Net Cash Flow	-7,274	-19,706	11,102	7,846	-353.61	-122.87
Free Cash Flow	4,423	7,863	9,693	264.71	-14,072	-7,088
Free Cash Flow Growth	-45.61%	-18.88%	3561.71%	-	-	-
Free Cash Flow Margin	9.67%	18.19%	23.91%	1.17%	-	-
Free Cash Flow Per Share	1.29	2.31	2.84	0.18	-14.03	-7.07
Cash Interest Paid	7,776	7,776	6,939	6,671	6,522	5,204
Cash Income Tax Paid	76.28	76.28	48.65	57.11	32.89	-

Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.